| Quantity: | |
|---|---|
Lenvatinib is a medication classified as a receptor tyrosine kinase inhibitor. It is used in the treatment of certain types of cancer, particularly thyroid cancer and renal cell carcinoma (a type of kidney cancer). Lenvatinib works by targeting and inhibiting the activity of multiple receptor tyrosine kinases, which are proteins involved in the growth and survival of cancer cells.
Here are some key points about lenvatinib:
Mechanism of Action: Lenvatinib inhibits the activity of various receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and platelet-derived growth factor receptors (PDGFR). By doing so, it interferes with signaling pathways that promote angiogenesis (the formation of new blood vessels) and tumor cell proliferation.
Indications: Lenvatinib is primarily used in the treatment of differentiated thyroid cancer that is refractory (does not respond) to radioactive iodine therapy. It is also indicated for the treatment of advanced renal cell carcinoma (RCC).
Administration: Lenvatinib is typically administered orally in the form of a daily tablet. It is important for patients to take the medication as prescribed by their healthcare provider.
Side Effects: Common side effects of lenvatinib may include fatigue, hypertension (high blood pressure), diarrhea, decreased appetite, weight loss, and nausea. It's important for patients to discuss potential side effects with their healthcare team.
Monitoring: Patients taking lenvatinib may require regular monitoring of blood pressure, thyroid function, and liver function during treatment.
Combination Therapy: In some cases, lenvatinib may be used in combination with other cancer treatments to enhance its effectiveness.
Lenvatinib is a medication classified as a receptor tyrosine kinase inhibitor. It is used in the treatment of certain types of cancer, particularly thyroid cancer and renal cell carcinoma (a type of kidney cancer). Lenvatinib works by targeting and inhibiting the activity of multiple receptor tyrosine kinases, which are proteins involved in the growth and survival of cancer cells.
Here are some key points about lenvatinib:
Mechanism of Action: Lenvatinib inhibits the activity of various receptor tyrosine kinases, including vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and platelet-derived growth factor receptors (PDGFR). By doing so, it interferes with signaling pathways that promote angiogenesis (the formation of new blood vessels) and tumor cell proliferation.
Indications: Lenvatinib is primarily used in the treatment of differentiated thyroid cancer that is refractory (does not respond) to radioactive iodine therapy. It is also indicated for the treatment of advanced renal cell carcinoma (RCC).
Administration: Lenvatinib is typically administered orally in the form of a daily tablet. It is important for patients to take the medication as prescribed by their healthcare provider.
Side Effects: Common side effects of lenvatinib may include fatigue, hypertension (high blood pressure), diarrhea, decreased appetite, weight loss, and nausea. It's important for patients to discuss potential side effects with their healthcare team.
Monitoring: Patients taking lenvatinib may require regular monitoring of blood pressure, thyroid function, and liver function during treatment.
Combination Therapy: In some cases, lenvatinib may be used in combination with other cancer treatments to enhance its effectiveness.
